Health-Care Industry Optimistic about Obesity Drugs Potential

Amid growing confidence in the potential of obesity drugs, health-care companies are witnessing a rise in their stocks. Companies like Novo Nordisk and Eli Lilly, the makers of this new class of drugs, experienced slight increases in their shares. The pharmaceutical industry expects an unprecedented concentration of drug sales in obesity drugs over the next decade, according to an unnamed venture-capital investor.

Merck’s Keytruda Shows Promise as Cancer Treatment

Merck announced that a late-stage trial of its blockbuster cancer drug Keytruda as a treatment for various types of non-small cell lung cancer (NSCLC) achieved its primary endpoint of overall survival. This development has garnered positive attention and has led to increased investor interest.

BioXcel Therapeutics’ Combination Treatment Indicates Potential

BioXcel Therapeutics saw a significant rise in its shares following promising results from a mid-stage trial of one of its products in combination with Keytruda. The positive outcomes showcase the potential benefits of this combination treatment, adding to the company’s credibility and further boosting investor confidence.

Setback for Akero Therapeutics with Lead Product Candidate

Shares of Akero Therapeutics took a dive after the company provided an update on its lead product candidate. The treatment, aimed at nonalcoholic steatohepatitis (NASH), a type of fatty liver disease, faced setbacks. This development raises concerns regarding the future prospects of Akero Therapeutics.

Canopy Growth Approved for Medical Cannabis in European Union

Canopy Growth, a prominent marijuana producer, experienced a surge in its shares after receiving approval for medical cannabis in the European Union. This achievement signifies a significant milestone for the company and indicates potential growth opportunities within the European market.